Curcumin: A therapeutic strategy for colorectal cancer?
| Autor: | Eva Martinez-Balibrea, Laura Layos, Vicenç Ruiz de Porras |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Curcumin Colorectal cancer medicine.medical_treatment Disease Targeted therapy 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Regorafenib Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Chemotherapy business.industry Cancer Immunotherapy medicine.disease Antineoplastic Agents Phytogenic 030104 developmental biology chemistry 030220 oncology & carcinogenesis Colorectal Neoplasms business |
| Zdroj: | Seminars in Cancer Biology. 73:321-330 |
| ISSN: | 1044-579X |
| Popis: | Colorectal cancer (CRC) is the second cause of cancer death worldwide. The metastatic disease is mainly treated with aggressive therapies consisting on combinations of cytotoxic chemotherapy plus anti-EGFR or anti-VEGF drugs. In spite of the improvements in clinical outcomes achieved in the last decade, these are the result of multiple new combinations using the existing therapeutic options and the introduction of regorafenib and TAS-102 in second or later lines of treatment. As immunotherapies are limited to less than 5% of CRC patients harboring tumors with deficient mismatch repair, there is an urgent need of finding new drugs to increase our patients' survival opportunities. Among all the natural products that are candidates to be used for the treatment of CRC cancer, curcumin (the golden spice) is in the spotlight. Used for centuries in the Ayurveda medicine, its demonstrated anticancer properties and low toxicity profile made it the focus of hundreds of preclinical and clinical investigations. So far we know that it can be combined with most of the aforementioned drugs in a safe and synergistic way. Regretfully, its poor bioavailability has been one of the main issues for its successful introduction in the clinic. Nevertheless, a plethora of new formulations with a huge increase in bioavailability are under study with promising results. In this review we discuss the possibility of incorporating curcumin in the treatment of CRC; specifically, we review preclinical and clinical data supporting its possible combination with current therapies as well as new formulations under clinical study. It is time for the golden spice revolution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect